167158-70-5

Basic information

• Product Name: 6-BROMO-2-CHLOROQUINAZOLIN-4(1H)-ONE
• Synonyms: 6-BROMO-2-CHLOROQUINAZOLIN-4(1H)-ONE;6-bromo-2-chloroquinazolin-4(3H)-one;6-Bromo-2-chloro-4(3H)-quinazolinone;2-Chloro-6-broMoquinazolin-4(3H)-one;6-Bromo-2-chloroquinazolin-4(3H)
• CAS NO: 167158-70-5
• Molecular Formula: C₈H₄BrClN₂O
• Molecular Weight: 259.48700
• Mol File: 167158-70-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 393.2oC at 760 mmHg
• Flash Point: 191.6oC
• Appearance: /
• Density: 1.95
• Vapor Pressure: 2.17E-06mmHg at 25°C
• Refractive Index: 1.737
• PKA: -3.76±0.20(Predicted)
• CAS DataBase Reference: 6-BROMO-2-CHLOROQUINAZOLIN-4(1H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-2-CHLOROQUINAZOLIN-4(1H)-ONE(167158-70-5)
• EPA Substance Registry System: 6-BROMO-2-CHLOROQUINAZOLIN-4(1H)-ONE(167158-70-5)

Safety Data

• Hazardous Substances Data: 167158-70-5(Hazardous Substances Data)

Usage

General Description

6-BROMO-2-CHLOROQUINAZOLIN-4(1H)-ONE is a chemical compound with the molecular formula C8H5BrClN2O. It is a quinazolin-4(3H)-one derivative that contains a bromo and chloro substituent at the 6 and 2 positions, respectively. 6-BROMO-2-CHLOROQUINAZOLIN-4(1H)-ONE has been the subject of research for its potential pharmacological properties, including its use as a building block in the synthesis of pharmaceutical drugs and other compounds. It has also been studied for its potential biological activities, such as antimicrobial and anticancer properties. Due to its unique structure and potential applications, 6-BROMO-2-CHLOROQUINAZOLIN-4(1H)-ONE is an important chemical compound with various research and industrial applications.

InChI:InChI=1/C8H4BrClN2O/c9-4-1-2-6-5(3-4)7(13)12-8(10)11-6/h1-3H,(H,11,12,13)

Upstream product

• 102393-82-8 6-bromo-2,4-dichloroquinazoline 
• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 
• 88145-89-5 6-bromo-1H-quinazoline-2,4-dione 

Downstream Products

• 1383987-36-7 2,4-difluoro-N-{2-(methyloxy)-5-[2-{[2-(methylsulfonyl)ethyl]amino}-4-oxo-3-(phenylmethyl)-3,4-dihydro-6-quinazolinyl]-3-pyridinyl}benzenesulfonamide 
• 1383991-64-7 6-bromo-2-{[2-(methylsulfonyl)ethyl]amino}-3-(phenylmethyl)-4(3H)-quinazolinone 
• 1383991-63-6 6-bromo-2-chloro-3-(phenylmethyl)-4(3H)-quinazolinone 

Relevant articles and documents

Synthesis and application of respiratory syncytial virus inhibitor

The invention provides synthesis and application of a respiratory syncytial virus inhibitor, and the inhibitor comprises a compound with a structure as shown in a formula I or pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope label of the compound. Compared with an existing RSV inhibitor, the compound has the advantages of high activity and higher in-vivo exposure.

Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. Following an oral dose, these noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and a lowering of blood glucose in animal models of diabetes. Alogliptin is currently undergoing phase 111 trials in patients with type 2 diabetes.